CEO Discusses Recent Stem Cell Breakthrough, Submission of Proposal to Department of Defense and Progress of Phase II Cancer Trial in Interview CLEVELAND, April 27 /PRNewswire-FirstCall/...
Date Change to June 12 CLEVELAND, April 4 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company will hold its 2007 annual stockholders...
CLEVELAND, March 26 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company is scheduled to present at the ValueRich Small-Cap Financial Expo...
Company plans to submit Protectan CBLB502 for Department of Defense request for proposal for medical radiation countermeasures to treat gastrointestinal effects of acute radiation syndrome...
CLEVELAND, Feb. 8 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company is scheduled to present at the Roth Capital Partners 19th Annual OC...
CLEVELAND, Feb. 6 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company is scheduled to present at the BIO CEO and Investor Conference to be...
CLEVELAND, Feb. 5 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company was featured in an article in the February 5, 2007, issue of...
CLEVELAND, Jan. 23 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI) (BSE:CFB), today announced that Chief Scientist Andrei Gudkov, Ph.D., D. Sci., was interviewed by...
Company to Receive up to $5 Million of Non-dilutive Funding from Roswell Park and Various New York Agencies CLEVELAND, Jan. 12 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI...
CLEVELAND, Aug. 31 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (Nasdaq: CBLI; Boston Stock Exchange: CFB), today announced that the company is scheduled to present at the Roth Capital...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관